OBJECTIVE-We previously showed that peroxisome proliferator-activated receptor (PPAR)-␥ in ␤-cells regulates pdx-1 transcription through a functional PPAR response element (PPRE). Gene Bank blast for a homologous nucleotide sequence revealed the same PPRE within the rat glucose-dependent insulinotropic polypeptide receptor (GIP-R) promoter sequence. We investigated the role of PPAR␥ in GIP-R transcription.
G
lucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid incretin hormone that binds to a seven-transmembrane G-proteincoupled receptor (GIP-R) that is expressed in numerous tissues including islet ␤-cells and ␣-cells (1, 2) . Its best-known actions in ␤-cells are to augment mealrelated insulin secretion and over the long-term to increase proinsulin synthesis and ␤-cell proliferation and survival (3, 4) . Several downstream signaling pathways from the ␤-cell GIP-R have been characterized. In contrast, little is known about GIP-R expression. A cAMP response element and SP1 and SP2 transcription factor binding sites are present in the 5Ј promoter region, but no physiologic modulators are known (4, 5) . As such, our understanding of GIP physiology is based solely on regulated GIP secretion and rapid metabolism to modulate its cellular actions. The one exception is the lowered number of ␤-cell GIP-R in animals (6, 7) and humans (8) with type 2 diabetes, and the resulting GIP resistance (9) , which results from hyperglycemia through an unknown mechanism (7, 10) .
Our laboratory has studied the biologic actions of PPAR␥ in ␤-cells and shown transcriptional regulation of the prodifferentiation transcription factor Pdx-1 (11, 12) . As part of our studies, we identified the PPAR response element (PPRE) within the pdx-1 promoter (12) . We now report finding the same PPRE sequence within the rat GIP-R promoter, followed by confirming physiologic and pharmacologic regulation of GIP-R transcription in ␤-cells by PPAR␥. Also, we provide evidence that the lowered ␤-cell GIP-R expression in hyperglycemic rats may result from impaired PPAR␥ expression.
Experimental methods. See the online appendix, available at http://diabetes.diabetesjournals.org/cgi/content/full/db09-1655/DC1. Statistical analysis. Data are presented as mean Ϯ SEM. Each data point from the animal studies was obtained from an individual rat or mouse. Statistical significance was determined by the unpaired Student's t test or two-way ANOVA.
RESULTS

GIP-R promoter PPRE.
We previously identified a functional PPRE in the mouse pdx-1 promoter (12). Gene Bank blast for this nucleotide sequence found a 100% identical sequence in the rat GIP-R promoter at positions Ϫ871 to Ϫ883 from the transcription start site (Gene Bank: AF050667) (supplemental Fig. 1A , available in the online appendix). MatInspector software (15) uncovered analogous sequences in the mouse and human GIP-R promoters (supplemental Fig. 1B) . INS-1 cell studies. Studies were performed in rat-derived INS-1 cells to confirm functionality of this putative PPRE. PPAR␥ binding was determined with the chromatin immunoprecipitation assay. Flanking primer pairs for a 213-bp PCR product that included the GIP-R PPRE (schema in supplemental Fig. 2A ) generated the correct-sized PCR band with input DNA and PPAR␥ antibody-precipitated DNA, whereas only faint bands were observed with nonimmune serum (Fig. 1A) . Representative negative and positive controls are shown in supplemental Fig. 2 .
PPAR␥ regulation of GIP-R expression was tested using four pooled siRNA duplexes against PPAR␥ in INS-1 cells that cause a 75% decrease in PPAR␥ protein (11) . Cells were treated with troglitazone or vehicle for 72 h (Fig. 1B) . GIP-R mRNA band intensity was markedly lowered in the PPAR␥ siRNA cells (lanes 1 and 4) . Troglitazone doubled it in control cells (lane 2), whereas the increase was eliminated when troglitazone and the PPAR␥ siRNA duplexes were used together (lane 3).
PPAR␥ regulation of GIP-R transcription was confirmed with a luciferase reporter gene assay that used a wild-type rat GIP-R promoter fragment and also those containing mutations in the DR1 and DR2 hexamers of the GIP-R PPRE (Mut-1 and Mut-2 fragments), subcloned into the pTAL luciferase reporter vector. The DR1 and DR2 mutations both lowered basal luciferase activity (Mut-1 63 Ϯ 9% of wild-type GIP-R, P Ͻ 0.015; Mut-2 38 Ϯ 8% of wild-type GIP-R, P Ͻ 0.002) (Fig. 1C) . Also, 24-h incubation with troglitazone (Fig. 1D ) stimulated expression of the wildtype GIP-R construct (162 Ϯ 8% of vehicle-treated wildtype cells, P Ͻ 0.002), whereas this effect was absent with both mutations. In vivo studies. In vivo testing of PPAR␥ regulation of ␤-cell GIP-R expression was carried out using PANC PPAR␥ Ϫ/Ϫ mice that have a pancreas-specific deletion of PPAR␥ from a Cre/loxP recombinase system with Cre driven by the pdx-1 promoter (14) . We previously reported that 8-week-old male PANC PPAR␥ Ϫ/Ϫ mice are modestly hyperglycemic, with a normal ␤-cell mass and normalappearing pancreas histology and islet cytoarchitecture (12) . The current studies confirmed the expected defect in GIP-R expression ( Fig. 2A, mRNA; Fig. 2B , protein 29 Ϯ 5% of control, P Ͻ 0.0001) in isolated islets from these mice. Immunofluorescence studies of pancreas sections showed markedly lowered GIP-R staining in islet ␤-cells and non-␤-cells of PANC PPAR␥ Ϫ/Ϫ mice versus control mice (Fig. 2C) .
Analogous studies were performed in normoglycemic Sprague-Dawley rats 14 days after 60% Px when islet nuclear PPAR␥ expression is 2.5-fold increased (11) . Comparable increases in GIP-R mRNA (Fig. 3A) and protein (Fig. 3B, 1 .9 Ϯ 0.2-fold of sham, P Ͻ 0.02) were found in Px versus sham rat islets. Also, GIP-R staining intensity was increased in islet ␤-cells and non-␤-cells versus the sham rats (Fig. 3C) . Troglitazone studies. Thiazolidinedione (TZD) stimulation of GIP-R expression was tested by incubating normal mouse islets for 72 h with troglitazone or vehicle. Troglitazone caused a near-tripling of the GIP-R protein level (supplemental Figs. 3A and B, 2.7 Ϯ 0.4-fold of DMSO islets, P Ͻ 0.02). Also the insulin response to 16.7 mmol/l glucose/10 nmol/l GIP peptide was nearly doubled (P Ͻ 0.05), whereas insulin responses to 2.8 mmol/l glucose with or without GIP peptide, and to high glucose alone, were unchanged (supplemental Fig. 3C ). Hyperglycemic rats. We speculated that impaired PPAR␥ expression caused the ␤-cell GIP-R depletion in animal models of type 2 diabetes (6,7). Accordingly, we performed PPAR␥ and GIP-R Western blots on islet extracts from 3-week postsurgery 60% Px and sham-operated ZF and ZL rats, based on our report that Px ZF rats are hyperglycemic (ϳ15 mmol/l) with the same degree of obesity and serum levels of nonesterified fatty acids and GIP as normoglycemic sham ZF rats (13) . Figure 4 shows that islet PPAR␥ and GIP-R protein levels are doubled in the sham ZF versus sham ZL rats (1.9 Ϯ 0.1-fold, P Ͻ 0.001; 2.2 Ϯ 0.3-fold, P Ͻ 0.01, respectively). In contrast, both are lowered by 60% in Px (hyperglycemic) ZF islets versus the sham (normoglycemic) ZF islets (0.7 Ϯ 0.1-fold and 0.8 Ϯ 0.1-fold of sham ZL islets, respectively).
DISCUSSSION
We used in vitro and in vivo techniques to show for the first time that GIP-R transcription in ␤-cells is regulated by PPAR␥. Also, that pharmacologic activation of PPAR␥ by TZDs induces the same effect resulting in greater GIP potentiation of glucose-induced insulin secretion. These results add to our prior studies of PPAR␥ signaling in ␤-cells that showed 40% of adult mouse islet pdx-1 expression is PPAR␥ regulated (11, 12) by our now finding a second gene with the identical PPRE and functional characteristics. There are several noteworthy implications to these results. First, Pdx-1 is considered the most important transcription factor in ␤-cells related to its essential role for normal ␤-cell function, viability, and compensation capacity (16) . Also, studies of incretin receptor knockout mice and in vivo usage of GIP-R peptide agonists have demonstrated a necessary role for GIP in normal mealtime glucose tolerance and insulin secretion (17, 18) . Clinical trials have found a particularly high success rate of TZDs in pre-diabetes and early type 2 diabetes, with the mechanism believed to be the peripheral insulin sensitization lowering the drive for insulin secretion (so-called "␤-cell rest") (19) . However, given the importance of the identified PPAR␥-regulated genes in ␤-cells, our results raise the possibility that direct PPAR␥-mediated effects on ␤-cells also account for some of the clinical benefits. Indeed, others have shown a direct effect of TZDs to restore Pdx-1 levels and reduce endoplasmic stress in islets from diabetic rats (20) .
FIG. 2. Islet GIP-R mRNA and protein expression, and pancreas immunostaining for GIP-R, in 8-week-old male PANC PPAR␥ ؊/؊ mice with a pancreas-specific knockout of PPAR␥ (KO) and littermate floxed control mice (Cre؊). Representative gels showing PCR products for islet GIP-R and cyclophilin (A) and immunoblots for GIP-R and
Second, there is the possibility we have uncovered an unknown feature of incretin physiology, i.e., variable GIP-R expression, related to our finding increased islet GIP-R expression in two rat models of ␤-cell compensation from unrelated causes: reduced ␤-cell mass in 60% Px Sprague-Dawley rats (21) and mutated leptin receptors resulting in obesity, insulin resistance, and hyperlipidemia in ZF rats (13) . This shared observation is particularly interesting, since there is no precedence for GIP-R hyperexpression except in the adrenocortical tumors of some individuals with Cushing's syndrome (22) . Also, our finding that the GIP-R hyperexpression in both models was paralleled by increased ␤-cell expression of PPAR␥ (11; Fig. 4) is consistent with the main conclusions of this study regarding PPAR␥ regulation of ␤-cell GIP-R expression. On the other hand, an in vitro study reported PPAR␣ regulates ␤-cell GIP-R expression and speculated this effect occurs in vivo related to the ␤-cell fatty acid load (23) . This mechanism seems unlikely in the 60% Px Sprague-Dawley rats, since serum triglyceride and free fatty acid levels are unchanged post-Px in lean rats (13, 21) , plus islet PPAR␣ expression is reduced (13) . In contrast, ZF rats are markedly hyperlipidemic (13) , making this a potential mechanism. Also the lack of a post-Px increase in PPAR␥ and GIP-R expression in ZL rats (Fig. 4) may reflect the different times of study-3 weeks post-Px in ZL rats versus 2 weeks post-Px in Sprague-Dawley rats.
The third implication of our results is our speculation that aberrant PPAR␥ signaling is a new mechanism for the lowered ␤-cell GIP-R expression and GIP resistance in animal and human type 2 diabetes (6 -9). Hyperglycemia causes this effect in animals (7, 10) , but no mechanistic details are known except for a study that reported accelerated GIP-R degradation in islets cultured at high glucose conditions (24) . Figure 4 supports our proposal by showing parallel reductions in islet expression of PPAR␥ and GIP-R in the hyperglycemic ZF rats. However, Px ZF rats also have a reduction in islet PPAR␣ mRNA expression (13) , so the exact mechanism is unknown. A related issue is the lowered ␤-cell expression for the other incretin hormone receptor (GLP-1) in animals and humans with type 2 diabetes (7, 8) . However, the molecular mechanism is likely different from the GIP-R depletion based on the study by Xu et al. (7) that performed 96-h glucose infusions in conscious rats and found islet GLP-1R mRNA levels fell 50%, whereas GIP-R mRNA levels modestly increased, plus they noted the same divergence in 2-day high glucose cultured islets. Also, it is likely that the lowered islet incretin receptor expression in type 2 diabetes is multifactorial, with recent interest in disrupted TCF7L2 signaling (8) . Thus, our results suggest that ␤-cell PPAR␥ regulation of GIP-R expression is a newly identified feature of incretin (patho)-physiology and TZD therapeutics. Also the lowered islet PPAR␥ expression in Px ZF rats (glycemia 15 mmol/l) may provide a new understanding why TZD therapy is so powerful in pre-diabetes and early type 2 diabetes as opposed to the more modest efficacy with advanced type 2 diabetes (19, 25) .
In summary, GIP-R is a newly described PPAR␥-regulated gene in ␤-cells. Expression of both genes is increased in rat models with ␤-cell adaptation to diverse stimuli. Also, TZDs augment GIP potentiation of glucose-induced insulin secretion through this mechanism. In contrast, this expression system is downregulated in diabetic rats. As such, our studies have uncovered a new mechanism for regulatory control of the ␤-cell GIP-R expression and may have added a new understanding to incretin (patho)-physiology and TZD therapy. 
